Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Deloitte
US Army
Teva
Healthtrust
Queensland Health

Generated: August 22, 2019

DrugPatentWatch Database Preview

Claims for Patent: 9,345,768

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,345,768
Title:Nanoparticle/active ingredient conjugates
Abstract: The present invention relates to nanoparticles, wherein at least one therapeutically active substance is bound to said nanoparticle and wherein the separation of the at least one therapeutically active substance from the nanoparticle is caused or initiated by an alternating magnetic filed. Furthermore, the present invention relates to pharmaceutical compositions, in particular to injection solutions containing the nanoparticles as well as to the use thereof for the treatment of cancer.
Inventor(s): Jordan; Andreas (Berlin, DE), Waldoefner; Norbert (Berlin, DE), Decken; Klaus (Berlin, DE), Scholz; Regina (Berlin, DE)
Assignee: MAGFORCE AG (Berlin, DE)
Application Number:11/911,196
Patent Claims:1. A nanoparticle composition, comprising a nanoparticle, at least one linker bound to the nanoparticle, and at least one therapeutically active substance bound to the nanoparticle via the linker, wherein the linker is composed of nucleic acids and wherein the linker is thermolabile and is adapted to be melted upon heating of the nanoparticle composition by an alternating magnetic field, wherein the melting occurs in the range of 40.degree. C. to 60.degree. C. which causes, initiates, or substantially enhances separation of the at least one therapeutically active substance from the nanoparticle.

2. The nanoparticle composition according to claim 1, wherein the linker is a double stranded nucleic acid construct, a double helix, a homo hybrid or a hetero hybrid from DNA-DNA, DNA-RNA, DNA-PNA, RNA-RNA, RNA-PNA or PNA-PNA.

3. The nanoparticle composition according to claim 1, wherein at least part of the nanoparticle is coated by a protective sheath or a coating.

4. The nanoparticle composition according to claim 3, wherein the protective sheath or coating comprises amino groups or carboxyl groups.

5. The nanoparticle composition according to claim 1, wherein the at least one therapeutically active substance is selected from the group comprising antiproliferative, antimigration, antiangiogenic, antithrombotic, anti-inflammatory, antiphlogistic, cytostatic, cytotoxic, anticoagulative, antibacterial, antiviral and/or antimycotic agents.

6. The nanoparticle composition according to claim 5, wherein the at least one therapeutically active substance is selected from the group comprising actinomycin D, ametantrone, 9-Aminocamptothecin, aminoglutethimide, amsacrine, anastrozole, antagonists of purine and pyrimidine bases, anthracycline, aromatase inhibitors, asparaginase, antiestrogens, bendamustine, bexarotene, biolimus A9, bleomycin, buserelin, busulfan, calicheamicins, camptothecin, camptothecin derivatives, capecitabine, carboplatin, carmustine, chlorambucil, cisplatin, cladribine, cyclophosphamide, cytarabine, cytosine arabinoside, alkylating cytostatics, dacarbazine, dactinomycin, daunorubicin, 5'-deoxy-5-fluorouridine, docetaxel, doxorubicin (adriamycin), doxorubicin lipo, epirubicin, estramustine, etoposide, exemestane, fludarabine, fluorouracil, folic acid antagonists, formestane, gemcitabine, glucocorticoids, goserelin, hormones and hormone antagonists, hycamtin, hydroxyurea, idarubicin, ifosfamide, imatinib, irinotecan, letrozole, leuprorelin, lomustine, maytansinoids, melphalan, mercaptopurine, methotrexate, miltefosine, mitomycins, mitopodozide, antimitotic agents, mitoxantrone, nimustine, oxaliplatin, oxazaphosphorines, paclitaxel, pentostatin, podophyllotoxin derivatives, procarbazine, rapamycin, rhodomycin D, tamoxifen, temozolomide, teniposide, testolactone, thiotepa, thioguanine, topoisomerase inhibitors, topotecan, treosulfan, tretinoin, triptorelin, trofosfamides, vinca alkaloids, vinblastine, vincristine, vindesine, vinorelbine, cytostatically active antibiotics.

7. The nanoparticle composition according to claim 5, wherein the at least one therapeutically active substance is selected from the group comprising nucleic acids, amino acids, peptides, proteins, carbohydrates, lipids, glycoproteins, glycans or lipoproteins, wherein the aforementioned substances have antiproliferative, anti-migration, antiangiogenic, antithrombotic, anti-inflammatory, antiphlogistic, cytostatic, cytotoxic, anticoagulative, antibacterial, antiviral and/or antimycotic properties.

8. The nanoparticle composition according to claim 1, wherein the nanoparticle comprises superparamagnetic iron oxides or pure iron having an oxide layer.

9. The nanoparticle composition according to claim 1, further comprising a sensitizer, radiosensitizer and/or amplifier bound to the nanoparticle for complementing conventional cancer treatment methods.

10. The nanoparticle composition according to claim 1, further comprising monoclonal antibodies or respectively antibody fragments and/or aptamers bound to the nanoparticle for conveying target finding properties to the nanoparticle composition.

11. A pharmaceutical composition comprising the nanoparticle composition of claim 1 and a pharmaceutically acceptable carrier, wherein the pharmaceutical composition is adapted for infusion or injection.

12. A method comprising administering the pharmaceutical composition of claim 11 to a mammal for the treatment of proliferative diseases, cancer and bacterial infections, wherein the administering is an administration to a tumor or infection site, followed by application of an alternating magnetic field.

13. A nanoparticle composition of claim 1, wherein the nanoparticle is adapted to be heated by an alternating magnetic field.

14. A nanoparticle composition of claim 1, wherein the separation of the at least one therapeutically active substance from the nanoparticle occurs at a temperature of more than 45.degree. C.

15. The nanoparticle composition of claim 1, wherein the linker is composed of oligonucleotides.

16. The nanoparticle composition of claim 1, wherein the therapeutically active substance is siRNA.

17. A nanoparticle composition, comprising a nanoparticle, at least one linker bound to the nanoparticle, and at least one therapeutically active substance bound to the nanoparticle via the linker, wherein the linker is composed of polypeptides, and wherein the linker is thermolabile and is adapted to be melted upon heating of the nanoparticle composition by an alternating magnetic field, wherein the melting occurs in the range of 40.degree. C. to 60.degree. C. which causes, initiates, or substantially enhances separation of the at least one therapeutically active substance from the nanoparticle.

18. The nanoparticle composition of claim 17, wherein the linker is composed of polypeptides which form homo dimers or hetero dimers.

19. A nanoparticle composition, comprising a nanoparticle, at least one linker bound to the nanoparticle, and at least one therapeutically active substance bound to the nanoparticle via the linker, wherein the linker is composed of nucleic acids or polypeptides, and wherein the linker is thermolabile and is adapted to be melted upon heating of the nanoparticle composition by an alternating magnetic field, wherein the melting occurs in the range of 40.degree. C. to 60.degree. C. which causes, initiates, or substantially enhances separation of the at least one therapeutically active substance from the nanoparticle.

20. A method comprising administering the pharmaceutical composition of claim 11 to a mammal for the treatment of cancer, wherein the administering is an intratumoral administration.

Summary for Patent: ➤ Sign Up

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2005 016 873Apr 12, 2005
PCT Information
PCT FiledApril 12, 2006PCT Application Number:PCT/DE2006/000653
PCT Publication Date:October 19, 2006PCT Publication Number:WO2006/108405

Details for Patent 9,345,768

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Merck ELSPAR asparaginase VIAL 101063 001 1978-01-10 ➤ Sign Up MAGFORCE AG (Berlin, DE) 2025-04-12 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
Colorcon
Deloitte
Fuji
Express Scripts
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.